Score Overview
Fulcrum Therapeutics Inc fundamental performance
Between 2020 and 2025, revenue declined from $ 8M to $ 0.00 and net income went from -$ 68M to -$ 74M. Revenue increased in 1 of those 5 years; net income in 2.
Fulcrum Therapeutics Inc currently holds a 5-year HDB Score of 3.0 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 3.72 | — |
1 Year2025-08-12 | $ 6.54 | -43.12% |
5 Years2021-08-12 | $ 22.45 | -83.43% |
All Time2019-07-18 | $ 13.50 | -72.44% |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | All Time2019-07-18 |
|---|---|---|---|---|
| Price | $ 3.72 | $ 6.54 | $ 22.45 | $ 13.50 |
| Return | — | -43.12% | -83.43% | -72.44% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 0.00 | -$ 84M | $ 318M |
| 2025 | $ 0.00 | -$ 74M | $ 352M |
| 2024 | $ 80M | -$ 9M | $ 241M |
| 2023 | $ 2M | -$ 97M | $ 236M |
| 2022 | $ 6M | -$ 109M | $ 202M |
| 2021 | $ 19M | -$ 78M | $ 218M |
| 2020 | $ 8M | -$ 68M | $ 112M |
| IPO2019 | $ 750K | -$ 79M | $ 96M |
Explore beyond FULC
You're looking at Fulcrum Therapeutics Inc. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
